Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Ulcerative Colitis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: During the Double-blind phase all participants will be blinded to treatment assignment.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04882007
- Collaborators
- Not Provided
- Investigators
- Study Director: Frederique Corallo, MD OSE Immunotherapeutics
Get Well Soon